Activmed Practices and Research, Inc

1. AstraZeneca Pharmaceuticals LP $6,770,038 24 payments
2. Ucb SA $1,354,050 37 payments
3. AstraZeneca UK Limited $477,399 10 payments
4. Amgen Inc. $202,468 17 payments
5. Novartis Pharmaceuticals Corporation $44,058 4 payments
6. Sage Therapeutics, Inc. $25,870 3 payments
7. Novo Nordisk AS $18,924 14 payments
8. E.R. Squibb & Sons, L.L.C. $17,003 3 payments
9. Guerbet LLC $990 4 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $6,390,552 8 payments
2. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $473,297 12 payments
3. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $456,849 7 payments
4. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria $406,538 4 payments
5. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $190,370 1 payment
6. A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $152,532 4 payments
7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $134,857 2 payments
8. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $104,408 4 payments
9. ABP 654 P3 PsO Study $93,063 6 payments
10. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $57,187 3 payments

1. Patient care $990 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.